An update on huperzine A as a treatment for Alzheimer's disease

John T. Little, Sally Walsh, Paul S. Aisen

Research output: Contribution to journalArticle

Abstract

Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is evidence that huperzine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). The drug is available as a nutriceutical in the US. However, there have been no published controlled clinical trials outside China assessing its toxicity and efficacy. This paper reviews the development of huperzine A as a treatment fof AD, including the Phase II trial now under way in the US.

Original languageEnglish (US)
Pages (from-to)209-215
Number of pages7
JournalExpert Opinion on Investigational Drugs
Volume17
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Alzheimer Disease
Cholinesterase Inhibitors
Huperzia
Controlled Clinical Trials
Dietary Supplements
China
Antioxidants
huperzine A
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitor
  • Dementia
  • Huperzine A
  • Neuroprotective

ASJC Scopus subject areas

  • Pharmacology

Cite this

An update on huperzine A as a treatment for Alzheimer's disease. / Little, John T.; Walsh, Sally; Aisen, Paul S.

In: Expert Opinion on Investigational Drugs, Vol. 17, No. 2, 02.2008, p. 209-215.

Research output: Contribution to journalArticle

Little, John T. ; Walsh, Sally ; Aisen, Paul S. / An update on huperzine A as a treatment for Alzheimer's disease. In: Expert Opinion on Investigational Drugs. 2008 ; Vol. 17, No. 2. pp. 209-215.
@article{baa5d0dbb7854c8399ba15b197002b56,
title = "An update on huperzine A as a treatment for Alzheimer's disease",
abstract = "Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is evidence that huperzine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). The drug is available as a nutriceutical in the US. However, there have been no published controlled clinical trials outside China assessing its toxicity and efficacy. This paper reviews the development of huperzine A as a treatment fof AD, including the Phase II trial now under way in the US.",
keywords = "Alzheimer's disease, Cholinesterase inhibitor, Dementia, Huperzine A, Neuroprotective",
author = "Little, {John T.} and Sally Walsh and Aisen, {Paul S.}",
year = "2008",
month = "2",
doi = "10.1517/13543784.17.2.209",
language = "English (US)",
volume = "17",
pages = "209--215",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - An update on huperzine A as a treatment for Alzheimer's disease

AU - Little, John T.

AU - Walsh, Sally

AU - Aisen, Paul S.

PY - 2008/2

Y1 - 2008/2

N2 - Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is evidence that huperzine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). The drug is available as a nutriceutical in the US. However, there have been no published controlled clinical trials outside China assessing its toxicity and efficacy. This paper reviews the development of huperzine A as a treatment fof AD, including the Phase II trial now under way in the US.

AB - Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is evidence that huperzine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). The drug is available as a nutriceutical in the US. However, there have been no published controlled clinical trials outside China assessing its toxicity and efficacy. This paper reviews the development of huperzine A as a treatment fof AD, including the Phase II trial now under way in the US.

KW - Alzheimer's disease

KW - Cholinesterase inhibitor

KW - Dementia

KW - Huperzine A

KW - Neuroprotective

UR - http://www.scopus.com/inward/record.url?scp=39049152973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049152973&partnerID=8YFLogxK

U2 - 10.1517/13543784.17.2.209

DO - 10.1517/13543784.17.2.209

M3 - Article

VL - 17

SP - 209

EP - 215

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 2

ER -